(E)-methyl 8-sec-butyl-2-oxo-6-(3-oxo-3-p-tolylprop-1-enyl)-2H-chromene-3-carboxylate | 1262101-90-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (E)-methyl 8-sec-butyl-2-oxo-6-(3-oxo-3-p-tolylprop-1-enyl)-2H-chromene-3-carboxylate
• 英文别名: methyl 8-butan-2-yl-2-oxo-6-[(E)-3-oxo-3-phenylprop-1-enyl]chromene-3-carboxylate
• CAS: 1262101-90-5
• 化学式: C₂₄H₂₂O₅
• 分子量: 390.436
• InChiKey: JRNVKTSOWHMAFV-ZHACJKMWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  69.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-butan-2-yl-2-hydroxy-5-[(E)-3-oxo-3-phenylprop-1-enyl]benzaldehyde 、 丙二酸二甲酯 在 哌啶 作用下， 以 甲醇 为溶剂， 反应 0.5h， 以78%的产率得到(E)-methyl 8-sec-butyl-2-oxo-6-(3-oxo-3-p-tolylprop-1-enyl)-2H-chromene-3-carboxylate
  参考文献：
  名称：

  Synthesis and in vitro evaluation of novel coumarin–chalcone hybrids as potential anticancer agents

  摘要：

  A series of coumarin-chalcone hybrids have been synthesized and evaluated for their in vitro cytotoxicity against a panel of four human cancer cell lines and normal fibroblasts (NIH3T3). Among 21 compounds screened, three compounds (23, 25 and 26) showed IC50 range from 3.59 to 8.12 mu M. The most promising compound 26 showed around 30-fold more selectivity towards C33A (cervical carcinoma) cells over normal fibroblast NIH3T3 cells with an IC50 value of 3.59 mu M. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.10.116

文献信息

• [EN] COUMARIN-CHALCONES AS ANTICANCER AGENTS<br/>[FR] COUMARINE-CHALCONES EN TANT QU'AGENTS ANTICANCÉREUX
  申请人：COUNCIL SCIENT IND RES

  公开号：WO2012017454A1

  公开（公告）日：2012-02-09

  The present invention relates to certain coumarin/chalcone compounds or a pharmaceutically acceptable salt thereof. The present invention particularly relates to the coumarin/chalcone compounds as anticancer agents useful for the treatment of cancer. The present invention also relates to the process of preparation of the said compounds.

  本发明涉及某些香豆素/香根素化合物或其药用可接受的盐。本发明特别涉及香豆素/香根素化合物作为抗癌剂，用于治疗癌症。本发明还涉及所述化合物的制备过程。
• COUMARIN-CHALCONES AS ANTICANCER AGENTS
  申请人：Sashidhara Koneni Venkata

  公开号：US20130210909A1

  公开（公告）日：2013-08-15

  The present invention relates to certain coumarin/chalcone compounds or a pharmaceutically acceptable salt thereof. The present invention particularly relates to the coumarin/chalcone compounds as anticancer agents useful for the treatment of cancer. The present invention also relates to the process of preparation of the said compounds.

  本发明涉及某些香豆素/香草醛化合物或其药用盐。本发明特别涉及香豆素/香草醛化合物作为抗癌药物，用于治疗癌症。本发明还涉及所述化合物的制备过程。
• US8815940B2
  申请人：——

  公开号：US8815940B2

  公开（公告）日：2014-08-26
• Synthesis and in vitro evaluation of novel coumarin–chalcone hybrids as potential anticancer agents
  作者：Koneni V. Sashidhara、Abdhesh Kumar、Manoj Kumar、Jayanta Sarkar、Sudhir Sinha

  DOI：10.1016/j.bmcl.2010.10.116

  日期：2010.12

  A series of coumarin-chalcone hybrids have been synthesized and evaluated for their in vitro cytotoxicity against a panel of four human cancer cell lines and normal fibroblasts (NIH3T3). Among 21 compounds screened, three compounds (23, 25 and 26) showed IC50 range from 3.59 to 8.12 mu M. The most promising compound 26 showed around 30-fold more selectivity towards C33A (cervical carcinoma) cells over normal fibroblast NIH3T3 cells with an IC50 value of 3.59 mu M. (C) 2010 Elsevier Ltd. All rights reserved.